Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death

Cancer

Volumn 101, Issue 9, 2004, Pages 2098-2105

  Wasserfallen, Jean Blaise ^a   Ostermann, Sandrine ^a   Pica, Alessia ^a   Mirimanoff, René Olivier ^a   Leyvraz, Serge ^a   Villemure, Jean Guy ^a   Stupp, Roger ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Chemotherapy; Economics; Glioblastoma; Quality of life; Radiotherapy

Indexed keywords

ALIZAPRIDE; METOCLOPRAMIDE; ONDANSETRON; PENTAMIDINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DACARBAZINE; EUROPE; FEMALE; GLIOBLASTOMA; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 7044237227     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20619     Document Type: Article

References (31)

1. Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med. 1998;168:114-120.
2. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg. 1978;49:333-343.
3. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas Grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicentre trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47:649-652.
4. Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G 61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321-324.
5. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, CCNU and vincristine in the adjuvant treatment of high grade astrocytoma. A Medical Research Council trial. J Clin Oncol. 2001;19:509-518.
6. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
7. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
8. Rodriguez LA, Levin VA. Does chemotherapy benefit the patient with a central nervous system glioma? Oncology (Huntingt). 1987;1:29-36.
9. Middleton MR, Grob JJ, Aaronson N, et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
10. Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
11. Brada M, Hoang-Xuang K, Rampling R, et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259-266.
12. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18:1481-1491.
13. Yung WK, Prados MD, Yaya TR, et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
14. Osoba D, Brada M, Yung WK, Prados MD. Heath-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 2000;36:1788-1795.
15. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857.
16. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367.
17. Hillner BE, Agarwala S, Middleton MR. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. J Clin Oncol. 2000;18:1474-1480.
18. Dinnes J, Cave C, Huang S, Major K, Milne R. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma. London: Queen's Printer and Controller of Her Majesty's Stationery Office, 2001.
19. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-1382.
20. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1:634-656.
21. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis. 1960;11:7-33.
22. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer. 1992;28A: 1328-1330.
23. Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neurooncol. 1992;14:243-253.
24. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871-1874.
25. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-1968.
26. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
27. Aaronson NK, Ahmedzai S, Bergman B, et al. The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
28. Osoba D, Aaronson N, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer specific instruments. Qual Life Res. 1996;5:139-150.
29. Silverstein MD, Cascino TL, Harmsen WS. High-grade astrocytomas: resource use, clinical outcomes and cost of care. Mayo Clin Proc. 1996;71:936-944.
30. Latif AZ, Signorini D, Gregor A, Whittle IR. The costs of managing patients with malignant glioma at a neuro-oncology clinic. Br J Neurosurg. 1998;12:118-122.
31. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.